---
title: "Bristol-Myers Squibb (NYSE:BMY) Stake Raised by TIAA Trust National Association"
description: "TIAA Trust National Association increased its holdings in Bristol-Myers Squibb by 245.5% in the 1st quarter. Other hedge funds have also bought shares of the company. Several equities research analyst"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/209426661.md"
published_at: "2024-07-21T22:53:49.000Z"
---

# Bristol-Myers Squibb (NYSE:BMY) Stake Raised by TIAA Trust National Association

> TIAA Trust National Association increased its holdings in Bristol-Myers Squibb by 245.5% in the 1st quarter. Other hedge funds have also bought shares of the company. Several equities research analysts have recently weighed in on BMY shares. Bristol-Myers Squibb's stock performance has been trading at $42.64. The company recently disclosed a quarterly dividend.

TIAA Trust National Association increased its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 245.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 419,445 shares of the biopharmaceutical company's stock after acquiring an additional 298,026 shares during the period. TIAA Trust National Association's holdings in Bristol-Myers Squibb were worth $22,747,000 at the end of the most recent reporting period.

Get **Bristol-Myers Squibb** alerts:

-   3 High-Yield Dividend Stocks for Income Now and Growth Later

Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $1,560,524,000. M&G Plc purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth about $392,608,000. Pzena Investment Management LLC raised its stake in shares of Bristol-Myers Squibb by 119.8% during the 1st quarter. Pzena Investment Management LLC now owns 12,293,913 shares of the biopharmaceutical company's stock worth $666,699,000 after purchasing an additional 6,701,097 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of Bristol-Myers Squibb by 97.2% during the 1st quarter. Van ECK Associates Corp now owns 7,949,173 shares of the biopharmaceutical company's stock worth $431,084,000 after purchasing an additional 3,918,234 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in shares of Bristol-Myers Squibb by 14.6% during the 4th quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company's stock worth $1,207,549,000 after purchasing an additional 2,998,228 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

## Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BMY shares. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating on the stock in a research note on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Thursday, June 27th. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a research note on Thursday, April 18th. Finally, Barclays cut their price objective on Bristol-Myers Squibb from $43.00 to $41.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus price target of $59.07.

  

-   Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore

**Read Our Latest Research Report on Bristol-Myers Squibb**

## Bristol-Myers Squibb Stock Performance

BMY traded up $0.25 during midday trading on Friday, reaching $42.64. The company's stock had a trading volume of 12,839,934 shares, compared to its average volume of 16,336,650. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $65.38. The stock has a market cap of $86.44 billion, a P/E ratio of -13.75, a PEG ratio of 15.55 and a beta of 0.44. The company has a fifty day simple moving average of $41.68 and a 200 day simple moving average of $47.02. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

-   Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the firm earned $2.05 EPS. Bristol-Myers Squibb's revenue for the quarter was up 4.7% compared to the same quarter last year. Research analysts expect that Bristol-Myers Squibb will post 0.55 earnings per share for the current year.

## Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.63%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb's payout ratio is presently -77.42%.

## Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

## Recommended Stories

-   Five stocks we like better than Bristol-Myers Squibb
-   Business Services Stocks Investing
-   Why This AI Stock is Rising Despite Tech Sell-Off
-   How to Know if a Stock Pays Dividends and When They Are Paid Out
-   Investors Are Moving into Bonds and Small Cap Stocks: Here's Why
-   Breakout Stocks: What They Are and How to Identify Them
-   MarketBeat Week in Review – 7/15 - 7/19

**Want to see what other hedge funds are holding BMY?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Exposed: 3 CENT Crypto to Explode June 24th? (From True Market Insiders) (Ad)## Should you invest $1,000 in Bristol-Myers Squibb right now?

Before you consider Bristol-Myers Squibb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.

While Bristol-Myers Squibb currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [BMY.US - Bristol Myers Squibb](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 百时美施贵宝｜8-K：2025 财年 Q4 营收 125 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/274969786.md) |
| 辉瑞在台湾开展新的 Elranatamab 研究，目标是收集现实世界的骨髓瘤数据 | 辉瑞公司（Pfizer Inc.，股票代码：PFE）正在台湾启动一项新的观察性研究，以评估其多发性骨髓瘤药物 elranatamab 在真实世界中的有效性。该研究旨在跟踪患者的治疗结果和治疗模式，尽管尚未开始招募参与者。此举预计将增强辉瑞的 | [Link](https://longbridge.com/en/news/276252273.md) |
| 华尔街大佬 Tepper 押注 AI：美光持仓激增 200%，新买韩国 ETF | 对冲基金大佬 Tepper 去年四季度精准狙击 AI 芯片赛道，豪掷逾 6 亿美元重仓美光科技和韩国芯片 ETF，今年已斩获约 30% 回报。全球内存短缺叠加 AI 算力狂潮，其芯片押注与软件股暴跌形成冰火两重天。 | [Link](https://longbridge.com/en/news/276213747.md) |
| 美股的 “危险信号” | 本月标普 500 指数成分股在八个交易日内下跌 7% 或以上的股票数量已经超过 100 只，直逼 2022 年美股熊市的水平。 虽然这不像新冠疫情或关税危机期间那样极端，但该指标超过 100 通常意味着更大范围的下滑，而这种情况目前还没有发 | [Link](https://longbridge.com/en/news/276185288.md) |
| 一文读懂 2026 年至今的全球市场：什么在涨？美股为何不行？这种趋势会持续吗？ | 高盛报告揭示 2026 年市场新风向：周期性资产上涨仍有空间；但 AI 等热门主题估值过高，高波动或成为未来常态；美元将持续疲软；建议警惕高估值板块，分散股票持仓、保持健康的非美敞口（包括新兴市场），以及较长期限指数波动率的做多头寸。 | [Link](https://longbridge.com/en/news/276406606.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
